Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

can buy Novo Nordisk’s insulin products for $35 per month for the next five years. The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its ...

Novo Nordisk has said that the introduction ... That suggests its top-selling insulin products like rapid-acting NovoRapid (insulin aspart), premix NovoMix (insulin aspart/insulin aspart protamine ...

They also asked Novo Nordisk to explain how patients now on Levemir will get access to "similar long-acting insulin products without gaps in coverage and at similar cost-sharing." Two other ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

The agreement requires Denmark-based manufacturer Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month for the next five years, even for people without health insurance.

Novo Nordisk (NVO) has reportedly settled a lawsuit filed by the state of Minnesota over the pricing of its insulin products by agreeing to cap costs at $35 per month. Under the settlement ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...